First gene therapy for prevalent pathologies in neurology receives FDA IND clearance – EG 427 initiating first-in-human clinical study

EG 427 announces that it has received Investigational New Drug clearance from the U.S. Food and Drug Administration for EG110A, a gene therapy for the treatment of Neurogenic Detrusor Overactivity in Spinal Cord Injury patients.